Literature DB >> 23762995

Prevalence of hepatitis E and hepatitis B dual infection in North India (Delhi).

Nim J Singh1, Archana Kumari, Roberto Catanzaro, Francesco Marotta.   

Abstract

BACKGROUND AND AIM: The prevalence of dual infection was 2.8% (26/927). Majority of these patients had presented with acute flare of a chronic liver disease (42.3%) followed by acute jaundice (38.5%).We found HEV infection to be was highly prevalent among 20 to 40 years of age group. In the case of HBV only 5.37% (5/93) children were affected in the age group 0-10 years.
METHODS: Serum samples from 1147 proven HEV infection suspected were collected and tested for HBsAg and HEV (IgM) antibodies using enzyme linked immunosorbent assay kits (bio Merieux, France).
RESULTS: There were the 32.16% (367/1141) HEV positive cases. We found maximum HEV positivity in the age group of 21-30 years. There were 2.8% (26/927) HEV and HBV dully infected patients. The total 44.68% (273/611) suspected of acute hepatitis/jaundice were HEV positive.
CONCLUSION: The HEV found to be was highly prevalent among 20 to 40 years of age group. The males were more frequent than females for HEV and HBV infection. In the children's, there were lower attack of both HEV and HBV. The maximum patients were having acute hepatitis/jaundice in both HEV and HBV infection. There were 26 dually infected patients in 12 months.

Entities:  

Mesh:

Year:  2012        PMID: 23762995

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


  2 in total

Review 1.  Epidemiology of hepatitis E virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

2.  Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report.

Authors:  Chau-Ting Yeh; Christopher Sung-Huan Yeh; Yu-De Chu; Yang-Jen Chiang
Journal:  J Med Case Rep       Date:  2018-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.